CoChat

Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA

Open access
Del Re, Marzia, Tiseo, Marcello, Bordi, Paola, D’Incecco, Armida, Camerini, Andrea, Petrini, Iacopo, Lucchesi, Maurizio, Inno, Alessandro, Spada, Daniele, Vasile, Enrico, Citi, Valentina, Malpeli, Giorgio, Testa, Enrica, Gori, Stefania, Falcone, Alfredo, Amoroso, Domenico, Chella, Antonio, Cappuzzo, Federico, Ardizzoni, Andrea, Scarpa, Aldo, Danesi, Romano · 2017 · Oncotarget
Cited by 83

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

// Marzia Del Re 1 , Marcello Tiseo 2 , Paola Bordi 2 , Armida D’Incecco 3 , Andrea Camerini 4 , Iacopo Petrini 5 , Maurizio Lucchesi 6 , Alessandro Inno 7 , Daniele Spada 8 , Enrico Vasile 6 , Valentina Citi 1 , Giorgio Malpeli 9 , Enrica Testa 8 , Stefania Gori 7 , Alfredo Falcone 6 , Domenico Amoroso 4 , Antonio Chella 10 , Federico Cappuzzo 3 , Andrea Ardizzoni 2 , Aldo Scarpa 9 , Romano Danesi 1 1 Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy 2 Medical Oncology Unit, Azienda Ospedaliero-Universitaria, Parma, Italy 3 Medical Oncology Unit, AUSL6, Istituto Toscano Tumori, Livorno, Italy 4 Medical Oncology Unit, AUSL12, Istituto Toscano Tumori, Lido di Camaiore, Italy 5 Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy 6 Medical Oncology Unit 2, Azienda Ospedaliero-Universitaria, Pisa, Italy 7 Medical Oncology Unit, Ospedale Sacro Cuore, Negrar, Italy 8 Medical Oncolgy Unit, Ospedale Santa Maria della Misericordia, Urbino, Italy 9 ARC-NET Research Centre and Department of Pathology and Diagnostics, Azienda Ospedaliero-Universitaria, Verona, Italy 10 Lung Diseases Unit, Azienda Ospedaliero-Universitaria, Pisa, Italy Correspondence to: Romano Danesi, email: romano.danesi@unipi.it Keywords: cell-free circulating tumor DNA, KRAS, EGFR, activating mutation, tyrosine kinase inhibitors Received: June 24, 2015 Accepted: December 29, 2015 Published: January 20, 2016 ABSTRACT Introduction: KRAS oncogene mutations ( MUT KRAS ) drive resistance to EGFR inhibition by providing alternative signaling as demonstrated in colo-rectal cancer. In non-small cell lung cancer (NSCLC), the efficacy of treatment with EGFR tyrosine kinase inhibitors (EGFR-TKIs) depends on activating EGFR mutations ( MUT EGFR ). However, inhibition of EGFR may select resistant cells displaying alternative signaling, i.e., KRAS , or restoration of EGFR activity due to additional MUT EGFR , i.e., the c.2369C > T ( p.T790M EGFR ). Aim: The aim of this study was to investigate the appearance of MUT KRAS during EGFR-TKI treatment and their contribution to drug resistance. Methods: This study used cell-free circulating tumor DNA (cftDNA) to evaluate the appearance of codon 12 MUT KRAS and p.T790M EGFR mutations in 33 advanced NSCLC patients progressing after an EGFR-TKI. Results: p.T790M EGFR was detected in 11 (33.3%) patients, MUT KRAS at codon 12 in 3 (9.1%) while both p.T790M EGFR and MUT KRAS codon 12 were found in 13 (39.4%) patients. Six patients (18.2%) were KRAS wild-type ( WT KRAS ) and negative for p.T790M EGFR . In 8 subjects paired tumor re-biopsy/plasma samples were available; the percent concordance of tissue/plasma was 62.5% for p.T790M EGFR and 37.5% for MUT KRAS . The analysis of time to progression (TTP) and overall survival (OS) in WT KRAS vs. MUT KRAS were not statistically different, even if there was a better survival with WT KRAS vs. MUT KRAS , i.e., TTP 14.4 vs. 11.4 months ( p = 0.97) and OS 40.2 vs. 35.0 months ( p = 0.56), respectively. Conclusions: MUT KRAS could be an additional mechanism of escape from EGFR-TKI inhibition and cftDNA is a feasible approach to monitor the molecular development of drug resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.6957

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 83

Metadata

Authors
Del Re, M., Tiseo, M., Bordi, P., D’Incecco, A., Camerini, A., Petrini, I., Lucchesi, M., Inno, A., Spada, D., Vasile, E., Citi, V., Malpeli, G., Testa, E., Gori, S., Falcone, A., Amoroso, D., Chella, A., Cappuzzo, F., Ardizzoni, A., Scarpa, A., & Danesi, R.
Venue
Oncotarget
Published
2016-01-20
Volume
8
Issue
8
Pages
13611-13619
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2256274387
Cited by
83
References
16
FWCI
13.24
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA. https://app.cochat.ai/papers/10.18632/oncotarget.6957
The paper
Del Re, M., Tiseo, M., Bordi, P., D’Incecco, A., Camerini, A., Petrini, I., Lucchesi, M., Inno, A., Spada, D., Vasile, E., Citi, V., Malpeli, G., Testa, E., Gori, S., Falcone, A., Amoroso, D., Chella, A., Cappuzzo, F., Ardizzoni, A., . . . Danesi, R. (2017). Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA. Oncotarget. https://doi.org/10.18632/oncotarget.6957

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.